- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01410760
PERfusion CT in the FOXFIRE Trial to Study Blood Flow to Liver Metastases (PERFORM)
June 19, 2012 updated by: University of Oxford
Perfusion Computed Tomography Pilot Study in the NCRN FOXFIRE Clinical Trial to Determine Blood Flow to Liver Metastases
The PERFORM study is a pilot study investigating the feasibility and usefulness of performing a novel CT (Computed Tomography)scanning technique called Perfusion CT(CTP) as an addition to normal CT scanning in patients recruited to the FOXFIRE trial.
All patients recruited to FOXFIRE at the Oxford Radcliffe Hospitals and University Hospitals of Leicester will be invited to take part.
FOXFIRE is a national randomised controlled trial in which patients with unresectable liver tumours secondary to colorectal cancer will receive treatment with standard chemotherapy alone, or with chemotherapy in combination with an internal radiotherapy treatment which delivers radioactive particles(SIR-spheres) to the liver via its own blood supply (radioembolisation).
In the FOXFIRE study a normal CT scan would usually be performed prior to the start of treatment and also three months after the commencement of treatment to assess the cancer's response to treatment, particularly whether the tumour has changed in size as a result of treatment.
Perfusion CT gives the normal information on changes in tumour size but also assesses whether the blood flow to the cancer has changed, which may allow earlier identification of treatment success compared to normal CT scans.
All patients consenting to participate in the PERFORM study will undergo four perfusion CT scans: one before the treatment starts, and one at the start of each of the second, third and fifth cycles of chemotherapy.
The aim is to determine the feasibility of measuring tumour perfusion for data analysis using perfusion CT and to establish if the tumour perfusion pattern at baseline or shortly after the start of therapy can predict response to radioembolisation or chemotherapy.
This research is funded by the National Institute for Health Research Biomedical Research Centre in Oxford and Oxfordshire Health Services Research Committee.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Oxford, United Kingdom, OX3 7LJ
- Recruiting
- Oxford Radcliffe Hospitals NHS Trust
-
Contact:
- Ricky A Sharma, MB BChir
- Phone Number: 01865 617322
- Email: ricky.sharma@oncology.ox.ac.uk
-
Sub-Investigator:
- Esme J Hill, MBChB
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who have given written informed consent to participate in the FOXFIRE clinical trial and have not yet started chemotherapy treatment in the trial.
- Serum creatinine and calculated glomerular filtration rate are less than the upper limit of normal (ULN) in blood tests performed up to 29 days before entry into the FOXFIRE clinical trial.
- Liver metastasis 1.0 to4.0 cm in cranio-caudal diameter on imaging performed up to 29 days before entry into the FOXFIRE clinical trial
Exclusion Criteria:
- True allergy to intravenous iodinated CT contrast
- Active medical or psychological illness that would render the patient unsuitable for the additional imaging proposed in this pilot study, at the discretion of the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Recruitment rate to this voluntary study and acquisition of sufficient data for perfusion analysis
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Correlation between the tumour perfusion pattern on perfusion CT studies at baseline and shortly after the start of therapy and morphological response by RECIST criteria on CT scan 3 months post therapy in both arms of the FOXFIRE trial.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ricky A Sharma, MB BChir, University of Oxford
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2011
Primary Completion (Anticipated)
April 1, 2013
Study Registration Dates
First Submitted
August 3, 2011
First Submitted That Met QC Criteria
August 4, 2011
First Posted (Estimate)
August 5, 2011
Study Record Updates
Last Update Posted (Estimate)
June 20, 2012
Last Update Submitted That Met QC Criteria
June 19, 2012
Last Verified
June 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10/H0505/95
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Oncolytics BiotechRecruitingmCRC | Ras-mutated Metastatic Colorectal Cancer | MSS Metastatic Colorectal CancerUnited States
-
Northwell HealthRecruitingColorectal Cancer MetastaticUnited States
-
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Not yet recruitingColorectal Cancer MetastaticChina
-
Northwell HealthRecruitingColorectal Cancer MetastaticUnited States
-
West China HospitalNot yet recruitingColorectal Cancer With Liver MetastaticChina
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
National Cancer Institute (NCI)WithdrawnMetastatic Colorectal Cancer | Colorectal Cancer | Microsatellite Stable Metastatic Colorectal CancerUnited States
-
The First Affiliated Hospital of Xiamen UniversityNot yet recruitingColorectal Cancer Metastatic | Fecal Microbiota Transplantation
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Lung | Resectable Colorectal CarcinomaUnited States
-
Sun Yat-sen UniversityNot yet recruitingColorectal Cancer Metastatic | Peritoneal Metastasis | Colorectal Cancer (CRC) | MSS Metastatic Colorectal Cancer | Peritoneal (Metastatic) Cancer
Clinical Trials on Perfusion CT scan
-
M.D. Anderson Cancer CenterActive, not recruiting
-
HyperfusionUniversity Hospital, GhentUnknownMetastatic Lung Cancer | Cancer, Lung | Metastatic Liver Cancer | Cancer Liver | Perfusion Computed Tomography Target LesionBelgium
-
Universitaire Ziekenhuizen KU LeuvenRecruitingStatus Epilepticus | Positron-emission Tomography | Ictal-interictal Continuum | Perfusion Weighted MRI | Perfusion CTBelgium
-
Centre Hospitalier Princesse GraceCompleted
-
Nationwide Children's HospitalOhio State UniversityRecruitingDiabetes Mellitus | Peripheral Artery Disease | Chronic Limb-Threatening IschemiaUnited States
-
University Hospital, ToursCompletedColorectal Cancer | Hepatic MetastasesFrance
-
UNC Lineberger Comprehensive Cancer CenterTerminatedThoracic | Pulmonary Injury | Heart InjuriesUnited States
-
Nova Scotia Health AuthorityCompleted
-
Nova Scotia Health AuthorityCompleted
-
University of ManitobaManitoba Medical Service FoundationCompleted